The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial
Abstract
Objective: To evaluate the safety and efficacy of a humanized monoclonal antibody against CD154 (IDEC‐131) in patients with active systemic lupus erythematosus (SLE). Methods: In this phase II, double‐blind, placebo‐controlled, multiple‐center, multiple‐dose study, 85 patients with mild‐to‐moderately active SLE were randomized to receive 6 infusions of IDEC‐131, ranging from 2.5 mg/kg to 10.0 mg/kg, or placebo over 16 weeks. Efficacy was assessed at week 20, primarily by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and secondarily, by multiple measures of disease activity. Safety was assessed through week 28 by clinical and laboratory evaluation. Immunogenicity studies were also performed. Results: SLEDAI scores improved from the baseline levels of disease activity in all groups, including the placebo group. However, these scores were not statistically different among the IDEC‐131 treatment and placebo groups at week 20. Evaluations of secondary variables did not indicate significant differences between the IDEC‐131 treatment and placebo groups. The type and frequency of adverse events were similar between the IDEC‐131 and placebo groups. Conclusion: IDEC‐131 administered at doses ranging 2.5–10.0 mg/kg over 16 weeks was safe and well tolerated in patients with SLE. Efficacy of the drug compared with placebo was not demonstrated. There were statistically significant improvements from baseline in all groups, including the placebo group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
CD40 AND CD154 IN CELL-MEDIATED IMMUNITY
Grewal, I. S., & Flavell, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.111 · Cited by 1,539
Signals and signs for lymphocyte responses
Janeway, C. A., & Bottomly, K. (1994) · Cell · doi:10.1016/0092-8674(94)90335-2 · Cited by 848
Mach, F., Schönbeck, U., Sukhova, G. K., Bourcier, T., Bonnefoy, J.-Y., Pober, J. S., & Libby, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1931 · Cited by 732
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H., & Cosimi, A. B. (2000) · Nature Medicine · doi:10.1038/72162 · Cited by 692
IMMUNE REGULATION BY CD40 AND ITS LIGAND GP39
Foy, T. M., Aruffo, A., Bajorath, J., Buhlmann, J. E., & Noelle, R. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.591 · Cited by 626
Desai-Mehta, A., Lu, L., Ramsey-Goldman, R., & Datta, S. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118643 · Cited by 517
Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
Anderson, J. J., Wells, G., Verhoeven, A. C., & Felson, D. T. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<22::aid-anr4>3.0.co;2-9 · Cited by 503
Cited by
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
CD40/CD154 Interactions at the Interface of Tolerance and Immunity
Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104533 · Cited by 683
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationPathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Moulton, V. R., Suarez-Fueyo, A., Meidan, E., Li, H., Mizui, M., & Tsokos, G. C. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.05.006 · Cited by 469
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Immune and Inflammatory Role in Renal Disease
Imig, J. D., & Ryan, M. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120028 · Cited by 356
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Karnell, J. L., Rieder, S. A., Ettinger, R., & Kolbeck, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.005 · Cited by 334
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases
Croft, M., & Siegel, R. M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.22 · Cited by 288
T cells as therapeutic targets in SLE
Crispín, J. C., Kyttaris, V. C., Terhorst, C., & Tsokos, G. C. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.60 · Cited by 271
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
Tang, T., Cheng, X., Truong, B., Sun, L., Yang, X., & Wang, H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107709 · Cited by 271
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, W. J., Zhong, J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2506 · Cited by 263
Self-citationLessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Metadata
- Authors
- Kalunian, K. C., Davis, J. C., Merrill, J. T., Totoritis, M. C., Wofsy, D., & for the IDEC‐131 Lupus Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-12
- Volume
- 46
- Issue
- 12
- Pages
- 3251-3258
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2009154052
- Cited by
- 336
- References
- 22
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.